Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: An open-label randomised controlled trial

The Lancet Oncology

Volumn 16, Issue 13, 2015, Pages 1380-1388

  Badwe, Rajendra ^a   Hawaldar, Rohini ^a   Nair, Nita ^a   Kaushik, Rucha ^a   Parmar, Vani ^a   Siddique, Shabina ^a   Budrukkar, Ashwini ^a   Mittra, Indraneel ^a   Gupta, Sudeep ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LETROZOLE; PACLITAXEL; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INDIA; INTENTION TO TREAT ANALYSIS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME; WOUND INFECTION; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDIA; INTENTION TO TREAT ANALYSIS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84952871468     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00135-7     Document Type: Article

References (33)

1. Sant M, Allemani C, Berrino F, et al. Breast carcinoma survival in Europe and the United States. Cancer 2004, 100:715-722. the European Concerted Action on Survival and Care of Cancer Patients (EUROCARE) Working Group.
2. Gunduz N, Fisher B, Saffer EA Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979, 39:3861-3865.
3. Braunschweiger PG, Schiffer LM, Betancourt S Tumour cell proliferation and sequential chemotherapy after primary tumour resection in C3H/hej mammary tumours. Breast Cancer Res Treat 1982, 2:323-329.
4. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989, 49:1996-2001.
5. Demicheli R, Retsky MW, Swartzendruber DE, Bonadonna G Proposal for a new model of breast cancer metastatic development. Ann Oncol 1997, 8:1075-1080.
6. Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004, 171:1071-1076.
7. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970. the European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group.
8. Khan SA, Stewart AK, Morrow M Does aggressive local therapy improve survival in metastatic breast cancer?. Surgery 2002, 132:620-626. discussion 626-27.
9. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006, 24:2743-2749.
10. Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988-2003 SEER data. Ann Surg Oncol 2007, 14:2187-2194.
11. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 2008, 247:732-738.
12. Ruiterkamp J, Ernst MF, van de Poll-Franse LV, Bosscha K, Tjan-Heijnen VC, Voogd AC Surgical resection of the primary tumour is associated with improved survival in patients with distant metastatic breast cancer at diagnosis. Eur J Surg Oncol 2009, 35:1146-1151.
13. Nguyen DH, Truong PT A debate on locoregional treatment of the primary tumor in patients presenting with stage IV breast cancer. Expert Rev Anticancer Ther 2011, 11:1913-1922.
14. Pathy NB, Verkooijen HM, Taib NA, Hartman M, Yip CH Impact of breast surgery on survival in women presenting with metastatic breast cancer. Br J Surg 2011, 98:1566-1572.
15. Pérez-Fidalgo JA, Pimentel P, Caballero A, et al. Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?. Breast 2011, 20:548-554.
16. Rashaan ZM, Bastiaannet E, Portielje JE, et al. Surgery in metastatic breast cancer: patients with a favorable profile seem to have the most benefit from surgery. Eur J Surg Oncol 2012, 38:52-56.
17. Harris E, Barry M, Kell MR Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann Surg Oncol 2013, 20:2828-2834.
18. Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007, 14:3345-3351.
19. Bafford AC, Burstein HJ, Barkley CR, et al. Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat 2009, 115:7-12.
20. Le Scodan R, Stevens D, Brain E, et al. Breast cancer with synchronous metastases: survival impact of exclusive locoregional radiotherapy. J Clin Oncol 2009, 27:1375-1381.
21. Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006, 13:776-782.
22. Neuman HB, Morrogh M, Gonen M, Van Zee KJ, Morrow M, King TA Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter?. Cancer 2010, 116:1226-1233.
23. Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol 2008, 15:3384-3395.
24. Hazard HW, Gorla SR, Scholtens D, Kiel K, Gradishar WJ, Khan SA Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 2008, 113:2011-2019.
25. Leung AM, Vu HN, Nguyen KA, Thacker LR, Bear HD Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res 2010, 161:83-88.
26. Badwe RA, Paramar V, Dinshaw KA, et al. Evidence-based management of breast cancer. Common cancers in India: evidence-based management 2003, 3. Tata Memorial Hospital, Mumbai, India.
27. Badwe RA, Parmar V, Hawaldar R, et al. Surgical removal of primary tumor in metastatic breast cancer: Impact on health-related quality of life (HR-QOL) in a randomized controlled trial (RCT). Proc Am Soc Clin Oncol 2014, 32(suppl 5S). abstr 1124.
28. Soran A, Ozmen V, Ozbas S, et al. Early follow up of a randomized trial evaluating resection of the primary breast tumour in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01). Cancer Res 2013, 73(24 suppl). abstr S2-03.
29. Pierga JY, Robain M, Jouve M, et al. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol 2001, 12:231-237.
30. Dominici L, Najita J, Hughes M, et al. Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat 2011, 129:459-465.
31. ten Kate M, Hofland LJ, van Grevenstein WM, van Koetsveld PV, Jeekel J, van Eijck CH Influence of proinflammatory cytokines on the adhesion of human colon carcinoma cells to lung microvascular endothelium. Int J Cancer 2004, 112:943-950.
32. Benish M, Bartal I, Goldfarb Y, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008, 15:2042-2052.
33. Badwe R, Hawaldar R, Parmar V, et al. Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol 2011, 29:2845-2851.